Cardiac MRI for Assessment of Cardiac Structure and Function Following Doxorubicin Based Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Cardiac Toxicity
- Sponsor
- University of Nebraska
- Enrollment
- 10
- Locations
- 1
- Primary Endpoint
- Left Ventricular Ejection Fraction (LVEF) and Global Strain Decrease After Doxorubicin Chemotherapy
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
RATIONALE: Diagnostic procedures, such as cardiac magnetic resonance imaging, may help doctors detect early changes in the heart caused by chemotherapy.
PURPOSE: This clinical trial is studying how well cardiac magnetic resonance imaging works in patients with newly diagnosed non-Hodgkin lymphoma or Hodgkin lymphoma receiving doxorubicin.
Detailed Description
OBJECTIVES: * To determine whether early myocardial structural and functional changes can be detected using cardiac MRI in patients with newly diagnosed non-Hodgkin lymphoma or Hodgkin lymphoma receiving doxorubicin hydrochloride-based chemotherapy. OUTLINE: Patients undergo cardiac MRI with gadolinium contrast prior to initiation of doxorubicin hydrochloride-based chemotherapy and 3 months after completion of six courses of chemotherapy for non-Hodgkin lymphoma and twelve courses of chemotherapy for Hodgkin lymphoma.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosis of non-Hodgkin lymphoma or Hodgkin lymphoma
- •o Newly diagnosed disease
- •Planning to receive doxorubicin hydrochloride-based chemotherapy solely at the University of Nebraska Medical Center
- •Fertile patients must use effective contraception
- •Able to lie flat for 90 minutes
- •Able to fulfill the requirements of the study
Exclusion Criteria
- •Not pregnant or nursing
- •No pacemaker
- •No chronic kidney disease stages 3-5 (glomerular filtration rate \< 60 mL/min)
- •No metallic foreign body not approved for MRI
- •No known hypersensitivity to gadolinium contrast or other required drugs in the study
- •No comorbidity or condition which, in the opinion of the investigator, may interfere with the assessments and procedures of this study
- •No prior chemotherapy
- •No prior radiotherapy to mantle or mediastinum
Outcomes
Primary Outcomes
Left Ventricular Ejection Fraction (LVEF) and Global Strain Decrease After Doxorubicin Chemotherapy
Time Frame: cMRI will be done prior to induction of doxorubicin based chemotherapy and at three months after completion of the doxorubicin based chemotherapy regimen.
A reduction of 10% in left ventricular ejection fraction (LVEF) between the two cMRI studies was considered a subclinical functional event. New or progressive myocardial delayed enhancement within ≥1 segment was deemed as a subclinical structural event. Global left ventricle (LV) radial, circumferential, and longitudinal strain data for each patient were compared between cMRI-1 and cMRI-2. The study had a fixed endpoint (3 months post-treatment)